Nelson Sun - 10 Sep 2026 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Reporting relationship: Chief Financial & Operating Officer
Issuer ticker: AARD
Reported as of: 10 Sep 2026
Net transaction value: -$394,957
SEC form: 4
Accepted by SEC: 11 Sep 2026, 20:14:00 UTC
Prior SEC filing: 11 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Nelson Sun

Key filing fact

Nelson Sun filed Form 4 for Aardvark Therapeutics, Inc. (AARD) on 11 Sep 2026.

Key facts

This page summarizes Nelson Sun's Form 4 filing for Aardvark Therapeutics, Inc. (AARD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Sep 2026, 20:14.

Change

Previous filing in this sequence was filed on 11 Feb 2026.
Current net transaction value: -$394,957.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002045377 Primary reporting owner

Sun Nelson

Relationship: Chief Financial & Operating Officer
Address: C/O AARDVARK THERAPEUTICS, INC., 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO
Signature: /s/ Nelson Sun
Signature date: 11 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AARD transaction

Common Stock, par value $0.00001 per share

Sale

Transaction value: $73,779
Shares: -14,754
Change %: -13%
Price: $5.00
Shares after: 97,475
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

AARD transaction

Common Stock, par value $0.00001 per share

Sale

Transaction value: $321,179
Shares: -62,000
Change %: -64%
Price: $5.18
Shares after: 35,475
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.

Footnote F2

The price reported in Column 4 reflects the weighted-average sales price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.0007, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F3

Includes 3,745 shares of common stock acquired pursuant to the Issuer's 2025 Employee Stock Purchase Plan on May 22, 2026.

SEC remarks

Chief Financial & Operating Officer